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It is well known that natural products are a rich source of compounds for applications in medicine,
pharmacy, and biology. However, the exact molecular mechanisms of natural agents in human health have
not been clearly defined. Here, we demonstrate for the first time that the polyphenolic phytoalexin
resveratrol promotes expression and activity of Argonaute2 (Ago2), a central RNA interference (RNAi)
component, which thereby inhibits breast cancer stem-like cell characteristics by increasing the expression
of a number of tumour-suppressive miRNAs, including miR-16, -141, -143, and -200c. Most importantly,
resveratrol-inducedAgo2resultedinalong-termgenesilencingresponse.Wealsofoundthatpterostilbene,
which is a natural dimethylated resveratrol analogue, is capable of mediating Ago2-dependent anti-cancer
activity in a manner mechanistically similar to that of resveratrol. These findings suggest that the dietary
intake of natural products contributes to the prevention and treatment of diseases by regulating the RNAi
pathway.
N
atural products are a rich source of valuable medicinal agents. More than half of the currently available
drugs are natural or related compounds. In the case of cancer, the percentage of natural compounds
exceeds 60%. Research on natural products as potential anti-cancer agents dates back to at least the
Egyptian Ebers Papyrus of 1550 B.C. However, more recent scientific investigations began with the studies of
Hartwell andco-workers onthe application ofpodophyllotoxin anditsderivativesasanti-cancer agents
1.Alarge
number of plant, marine, and microbial sources have been tested, and hundreds of active compounds have been
isolated. Despite these advances, the underlying mechanisms of natural products in human health are not fully
understood.
Resveratrol, which is a multi-functional polyphenolic compound, is a phytoalexin present in a wide variety of
plant species, including grapes, mulberries, and peanuts
2. Since its discovery, resveratrol has been shown to
exhibit a plethora of physiological properties that may be useful in human medicine. More interest was focused
on resveratrol at the beginning of the 1990s when it was first shown to be present in red wine
3. Experimental
studies have shown that resveratrol inhibits the growth of various cancer cells and induces apoptotic cell death
4,5.
Recently,aphaseI/IIclinicaltrialinpatientswithcoloncancerwasconductedtoexaminetheeffectsofresveratrol
treatment on colon cancer progression and colonic mucosa in patients with colon cancer and its effects in
modulating the Wnt signalling pathway
2. Although these data provide evidence of multiple anti-tumour effects
induced by resveratrol, the exact mechanism is not clearly understood.
MicroRNAs (miRNAs) have emerged as key post-transcriptional regulators of gene expression that are
involved in diverse physiological and pathological processes
6. The inhibition of the miRNA biogenesis pathway
resultsinseveredevelopmentaldefectsandlethalityinmanyorganisms
7.Ithasbeensuggestedthataconsiderable
number of miRNAs have roles in cancer cells. Indeed, an increasing number of experimental studies have shown
that the knock-down or the re-expression of specific miRNAs could induce drug sensitivity, inhibit the prolif-
eration of cancer cells, and suppress cancer cell invasion and metastasis
8–10. Recent studies have shown that
natural products, including curcumin, isoflavone, I3C, DIM, and EGCG, could alter the expression of specific
miRNAs, which may lead to the increased sensitivity of cancer cells to conventional anti-cancer agents and,
therefore, tumour growth inhibition
11–14.However, theexact molecular mechanism of miRNA induction and the
biological significance of resveratrol-induced miRNAs have not been reported.
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nants
15.Dietarycomponentshavebeenimplicatedinmanypathways
involved in carcinogenesis. In addition, carcinogenic processes are
associated with the altered expression of several miRNAs. Recent
studies have reported that a widespread down-regulation of
miRNAs is commonly observed during human cancer-cell initiation
and progression
16,17. In this study, we hypothesised that the dietary
intake of natural products maintains tumour-suppressive miRNA
expression in cancer cells, leading to the prevention of carcinogen-
esis. We demonstrated that resveratrol suppresses cancer cell malig-
nancy in vitro and in vivo through the transcriptional activation of
tumour-suppressivemiRNAsandArgonaute2(Ago2).Furthermore,
we provided evidence that Ago2 over-expression enhances the RNA
interference (RNAi) activity. These findings suggest that the dietary
intake of natural products safely reduces a wide range of negative
consequences with an overall improvement in human health and
survival by modulating miRNA biogenesis.
Results
Resveratrol reduces the cancer stem-like cells population by up-
regulating miR-141 and miR-200c. To identify the potential anti-
cancer activity of resveratrol, we investigated the effects of this
compound on tumour formation in vivo. We orthotopically
inoculated female SCID hairless outbred mice with MDA-MB-231-
luc-D3H2LN cells (200 cells), which were then treated with
resveratrol (25 mg/kg/day) or ethanol (control) via intraperitoneal
injection every day for one week. Tumour growth was then
monitored using an IVIS imaging system. The weight of the mice
did not significantly change between the groups during the course of
the experiment, suggesting that resveratrol did not have notable
adverse effects on mice (Supplementary Fig. 1a). The results
demonstrated that the resveratrol administration into the mice
significantly suppressed tumour formation, while obvious tumours
were observed in vehicle-treated mice, indicating that resveratrol is
capable of inhibiting the survival and growth of cancer cells in vivo
(Fig. 1a). A recent report has shown that solid tumours contain a
distinct population of cells with the ability to form tumours in mice;
these cells are known as tumour-initiating or cancer stem-like cells
(CSCs) and display increased drug resistance and metastatic ability
because they consistently form tumours, whereas other cancer cell
populations were depleted of cells capable of tumour formation
18,19.
To identify the effects of resveratrol on the CSC phenotype, breast
cancercellswereexaminedforchangesintheCSCpopulation,which
is a highly tumourigenic CD44
1/CD24
2 subpopulation with stem
cell-like self-renewal properties and the ability to produce
differentiated progeny after resveratrol treatment
18. Compared to
vehicle-treated control cells, cells treated with 50 mM resveratrol
demonstrated a significant 6-fold decrease in the CD44
1/CD24
2
population in MDA-MB-231-luc-D3H2LN cells (Fig. 1b). In
addition, mammosphere formation, which has been widely used
for breast CSC enrichment, of the CD44
1/CD24
2 fraction from
MDA-MB-231-luc-D3H2LN cells was suppressed after resveratrol
treatment(SupplementaryFig.1b).Wealsoassessedapoptosisusing
TUNEL staining and a caspase assay and found that resveratrol did
notinduceapoptosis(SupplementaryFigs.1cand1d).Humanbreast
cancers are driven by a CSC component that may contribute to
tumour metastasis and therapeutic resistance
20. Indeed, we found
that the combination of resveratrol with low therapeutic doses of
docetaxel elicits significantly greater cancer cell growth inhibition
in vitro and in vivo (Supplementary Figs. 1e–g). These findings
strongly suggest that resveratrol demonstrates multiple anti-cancer
effects through the reduction of the CSC population.
To examine whether resveratrol could influence the breast cancer
cell metastasis ability, the highly invasive breast cancer cell line
MDA-MB-231-luc-D3H2LN was used in in vitro invasion assays.
As shown in Fig. 1c, the invasion of MDA-MB-231-luc-D3H2LN
cells was suppressed by resveratrol treatment. Previous studies have
documented aberrant miRNA expression in cancer, and our obser-
vations prompted us to hypothesise that the anti-cancer resveratrol
effectsweremediatedbymiRNAs,particularlybyagroupoftumour-
suppressive miRNAs
21. A recent study has demonstrated that miR-
141 and miR-200c strongly inhibit breast cancer invasion ability
22.
We found that resveratrol exposure increases miR-141 and miR-
200c expression in MDA-MB-231-luc-D3H2LN cells (Fig. 1d).
These findings suggest that resveratrol exhibits multiple anti-cancer
effects through the inhibition of CSC phenotypes by activating miR-
141 and miR-200c. In addition, to determine whether the up-regu-
lation of miR-141 and miR-200c is mediated at the transcriptional
level, we measured the expression levels of the primary miRNAs of
miR-141 and miR-200c and found that these miRNAs are up-regu-
lated at the primary transcript level (Supplementary Fig. 1h). Taken
together, these results indicate that resveratrol increases the express-
ion of tumour-suppressive miRNAs via the induction of miRNA
transcription. Similar results were obtained in two other human
breast cancer cell lines (MCF7 and MCF7-ADR) and MCF10A, an
immortalised, non-transformed epithelial cell line (Supplementary
Figs. 2–4).
Resveratrol up-regulates the expression of tumour-suppressive
miRNAs. We demonstrated that resveratrol specifically reduced the
CSC fraction (Fig. 1b). In addition, we also observed that miR-141 and
miR-200c, which are known to suppress the CSC phenotype, are both
induced by resveratrol treatment (Fig. 1d). These observations suggest
that a part of the anti-cancer effects of resveratrol is mediated by
miRNAs, particularly tumour-suppressive miRNAs. Indeed, a morpho-
logical change is observed after resveratrol treatment (Fig. 2a), sug-
gesting that resveratrol induces a variety of miRNAs in cancer cells.
To confirm whether miRNAs are globally up-regulated in the multi-
ple anti-cancer effects induced by resveratrol in MDA-MB-231-luc-
D3H2LN cells, we performed a comprehensive miRNA profiling of
untreated MDA-MB-231-luc-D3H2LN cells and compared the re-
sults to those obtained in resveratrol-treated cells. As shown in
Fig. 2b, we found that a subset of tumour-suppressive miRNAs is
transcriptionally up-regulated by resveratrol (Table 1). To validate the
microarray results, we performed qRT-PCR. A set of mature tumour-
suppressive miRNAs, including miR-16 and miR-143, are significantly
up-regulated in a variety of breast cancer cell lines, including MDA-
MB-231-luc-D3H2LN, MCF7, MCF7-ADR, and MCF10A (Supple-
mentary Figs. 2–5). These results indicated that resveratrol globally
up-regulates tumour-suppressive miRNAs in human breast normal
epithelial and cancer cells.
Resveratrol enhances the Ago2 RNAi potency. Although our data
provide evidence that resveratrol globally up-regulates tumour-
suppressive miRNAs and one of the mechanisms that is mediated
by primary miRNA up-regulation, we also hypothesised that chan-
ges at other levels of the RNAi pathway may play a role in enhancing
the resveratrol-mediated miRNA activity in cells in addition to tran-
scriptional alterations. It is known that miRNA generation occurs in a
multi-step process
23,24. If one of the components associated with the
miRNA pathway is under-expressed or qualitatively impaired, the
pathway as a whole is destabilised. To examine the effect of re-
sveratrol on the miRNA machinery, we measured the expression
levels of a selected group of miRNA machinery-related genes, in-
cluding Dicer1, Drosha, TARBP2, DGCR8, and Ago2, after the re-
sveratrol treatment of MDA-MB-231-luc-D3H2LN cells. We found
that resveratrol exposure significantly increased Ago2 expression in
MDA-MB-231-luc-D3H2LN cells (Fig. 2c and Supplementary Fig.
6a). To elucidate the resveratrol-mediated Ago2 up-regulation
mechanism, we assessed the Ago2 promoter activity and the Ago2
mRNA and protein half-lives after resveratrol treatment. As shown in
supplementary Fig. 6b, the Ago2 protein half-lives were unchanged
after resveratrol treatment. In contrast, the Ago2 mRNA was slightly
www.nature.com/scientificreports
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addition, resveratrol induced the luciferase activity of a plasmid
containing the Ago2 promoter upstream of the luciferase gene,
suggesting that resveratrol transcriptionally induced the expression of
Ago2 (Supplementary Fig. 6d). The Ago2 protein is a key regulator of
miRNA homeostasis and, upon recognition, it can either cleave or
remain tethered to an mRNA to repress its translation and/or
regulate its stability
25. To reveal the relationship between Ago2 and
miRNAs, we first quantified the miRNA expression in MDA-MB-
231-luc-D3H2LN cells transfected with the Ago2 expression vector.
The induction of Ago2 expression by the Ago2 expression vector
was confirmed by qRT-PCR (Fig. 2d). After transfection of the Ago2
expression vector, a subset of miRNAs including miR-16, miR-141,
miR-143, and miR-200c was higher than in the control cells (Fig. 2e
and Supplementary Fig. 6e). To further study the relationship between
resveratrol-induced Ago2 and RNAi activity, MDA-MB-231-luc-
D3H2LN cells were transfected with luciferase siRNA in the
presence of resveratrol treatment and subjected to an in vitro firefly
luciferase assay. If the induction of Ago2 expression leads to the
enhancement of RNAi activity in cells, the luciferase siRNA silencing
effect of the luciferase gene in MDA-MB-231-luc-D3H2LN cells may
be enhanced after Ago2 over-expression even in the presence of a low
siRNA dose and a prolonged period after siRNA transfection. As
shown in Fig. 2f, the resveratrol-induced Ago2 resulted in a long-
term gene-silencing response in MDA-MB-231-luc-D3H2LN cells.
In addition, Ago2 over-expression in HEK293 cells demonstrated a
long-term gene-silencing response that was similar to resveratrol-
treated MDA-MB-231-luc-D3H2LN cells (Supplementary Fig. 6f).
Figure 1 | Multiple anti-cancer effects ofresveratrol through the activation ofmiR-141 andmiR-200c. (a)MDA-MB231-luc-D3H2LN cells (200cells)
were injected into the mammary fat pad of six-week-old female SCID hairless outbred mice (n 5 5). They were then treated with resveratrol (25 mg/kg/
day) by intraperitoneal injection every day for 8 days. Tumour growth was monitored by injecting luciferin in the mice followed by measuring
bioluminescence using an IVIS imaging system. Representative mouse images at day 8 (upper panel) and quantified bioluminescence images at day 8
(lower panel) are shown. (b) MDA-MB231-luc-D3H2LN cells were treated with resveratrol or DMSO (control) at the specified doses for 3 days. The
percentage of CD44
1/CD24
2 cells after compound treatment in independent experiments with MDA-MB231-luc-D3H2LN cell populations is shown.
The CD44
1/CD24
2 denoting the CSC-enriched fraction. (c) MDA-MB231-luc-D3H2LN cells were grown, treated with resveratrol or DMSO (control)
for 1 day, and then subjected to an invasion assay. Representative photographs (upper panel) and quantification (lower panel) are shown. Scale bar: 100
mm.(d)ThemiR-141andmiR-200cexpressionlevelsinMDA-MB231-luc-D3H2LNcells.TheexpressionlevelsoftheindicatedmiRNAswereexamined
in MDA-MB231-luc-D3H2LN cells after 48 hour resveratrol treatment (all data are shown as the mean 6 s.e.m., *P,0.05, **P,0.01, ***P,0.001).
www.nature.com/scientificreports
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resveratrol treatment and then assessed the RNAi activity
demonstrated by the luciferase siRNA directed against the luciferase
gene. The reduction in Ago2 expression by Ago2 siRNA was confirmed
by qRT-PCR (Supplementary Fig. 6g). As shown in Fig. 2g, Ago2
siRNA-mediated silencing inhibited the RNAi activity in MDA-MB-
231-luc-D3H2LN cells. Taken together, these results indicate that the
resveratrol anti-cancer activities were mediated by not only tumour
suppressive miRNA upregulation but also by the enhancement of the
RNAi activity regulated by Ago2.
Resveratrol-induced miRNA exert an anti-cancer effect. It has
been reported that miR-141 inhibits the epithelial-mesenchymal
transition and cancer cell migration in breast cancer cells
26.I n
addition, we found that resveratrol induced the expression of miR-
141 and miR-200c in MDA-MB-231-luc-D3H2LN cells (Fig. 1d). In
Figure 2 | Association between resveratrol and Ago2. (a) Characteristic microscopic images of MDA-MB231-luc-D3H2LN cells in the presence of
DMSO (control) or resveratrol. Scale bar: 100 mm. (b) The effects of resveratrol treatment on miRNA expression in MDA-MB231-luc-D3H2LN cells by
miRNAmicroarrayanalysis.TheproportionsofmiRNAsatdifferentfoldchangelevelsareshowninthelowerpanel.(c)MDA-MB231-luc-D3H2LNcells
were treated with resveratrol or DMSO (control). After 2 days of culture, the cell extract was subjected to real-time mRNA qRT-PCR. (d), (e) MDA-
MB231-luc-D3H2LN cells were grown and transiently transfected with Ago2 or EGFP-IRES vector (control). After 2 days of culture, the cell extract was
subjectedtoreal-timemRNA(d)andmiRNA(e)qRT-PCR.Thevaluesonthey-axisaredepictedrelativetotheexpressionleveloftheEGFP-IREScontrol
vector, which is defined as 1. (f) MDA-MB231-luc-D3H2LN cells were grown and transiently transfected with luciferase siRNA or AllStars negative
control siRNA (0.1 nM) under resveratrol treatment. After 1, 3, or 5 days of culture, the cells were subjected to a luciferase reporter assay. The valueso n
they-axisaredepictedrelativetotheluciferaseactivityoftheAllStarsNegativeControlsiRNA,whichisdefinedas1.(g)MDA-MB231-luc-D3H2LNcells
were grown and transiently transfected with luciferase siRNA or AllStars Negative Control siRNA and Ago2 siRNA or AllStars Negative Control siRNA.
After 3 days of culture, the cells were subjected to a luciferase reporter assay. The values on the y-axis are depicted relative to the luciferase activity of the
negative control siRNA, which is defined as 1 (all data are shown as the mean 6 s.e.m., *P,0.05, **P,0.01, ***P,0.001).
www.nature.com/scientificreports
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evidenceofwhethermultiplephenotypesinducedbyresveratrolwere
regulated by tumour-suppressive miRNAs, MDA-MB-231-luc-
D3H2LN cells were transfected with an antisense oligonucleotide
targeting miR-141 (i.e., a miR-141 inhibitor) in the presence of
resveratrol treatment. MiR-141 repression by the miR-141
inhibitor was confirmed by qRT-PCR (supplementary Fig. 7a). As
shown in Fig. 3a, the miR-141-induced inhibition of invasion was
abrogated by the addition of the miR-141 inhibitor, and the MDA-
MB-231-luc-D3H2LN cell invasiveness was increased. To confirm
the link between resveratrol and miRNA expression, we investigated
the growth of breast cancer cells in the presence or absence of a miR-
143 inhibitor
27. In the presence of resveratrol, miR-143-induced
inhibition significantly increased the survival of MDA-MB-231-
luc-D3H2LN cells relative to the control (Fig. 3b). It has been
shown that miR-200c up-regulation in breast cancer cells inhibits
Zeb1 expression, resulting in E-cadherin induction in breast cancer
cell lines
28. As shown in Fig. 1d, we found miR-200c up-regulation
after resveratrol treatment, suggesting that resveratrol treatment
activates this pathway and demonstrating its anti-cancer activity.
Indeed, resveratrol addition significantly suppressed Zeb1
expression in the breast cancer cell lines (Fig. 3c) and induced E-
cadherin expression in those cells (supplementary Fig. 7b).
Furthermore, to show the direct effects of resveratrol on the
miRNA machinery, we performed a Zeb1 39UTR assay and
demonstrated that resveratrol treatment significantly down-
regulated the luciferase activity of a plasmid containing the Zeb1
39UTR (Fig. 3d). Taken together, these results suggested that
resveratrol plays an important role in breast cancer prevention by
up-regulating tumour-suppressive miRNAs.
The stilbene family regulates miRNA biogenesis. The naturally
occurring dimethylether resveratrol analogue pterostilbene is a
stilbene family member that is generated by plants. Pterostilbene
has also been reported to possess chemopreventive activity in
cancer and other resveratrol-like health benefits
29,30. To determine
whetherpterostilbeneinducedtheexpressionoftumour-suppressive
miRNAs in a similar manner as resveratrol, we assessed the effect of
pterostilbene on miRNA expression. As shown in Fig. 4a,
pterostilbene treatment suppressed cell growth more significantly
than resveratrol treatment in MDA-MB-231-luc-D3H2LN cells. In
addition, the expression of tumour suppressive miRNAs (i.e., miR-
143 and miR-200c) and Ago2 was significantly higher in
pterostilbene-treated MDA-MB-231-luc-D3H2LN cells than in
resveratrol-treated cells (Figs. 4b-d and Supplementary Fig. 8).
Taken together, these results suggest that resveratrol-induced
tumour-suppressive miRNA expression and its anti-cancer activity
are conserved among stilbene family members (Fig. 4e).
Discussion
Resveratrol exhibits strong anti-oxidant activity and is capable of
inducing apoptosis in cancer cells. Therefore, resveratrol is believed
to be efficacious at multiple carcinogenesis stages
4. However, the
underlying molecular mechanism of its anti-tumour activity has
yet to be defined. In this study, we demonstrated that resveratrol
up-regulated tumour-suppressive miRNAs, resulting in the induc-
tion of an anti-cancer effect against the CSC phenotype in cancer
cells. We also demonstrated that resveratrol inhibited the invasive-
nessofbreastcancercellsasoneoftheCSCphenotypesbyactivating
miR-141 and miR-200c. However, the reason why resveratrol
reduces the CSC population remains elusive. Recent studies have
provided evidence that miR-200c strongly inhibits the ability of
breast CSCs to form tumours in vivo
31. These findings suggest that
resveratrol shows multiple anti-cancer effects by reducing the CSC
population through miR-200c activation.
Argonauteproteins arewidelyexpressed andareinvolvedinpost-
transcriptionalgenesilencing.Usingmicroarraystocomparecontrol
and Ago2
2/2 cells, recent studies have demonstrated that Ago2 loss
results in the global reduction of mature miRNAs in erythroblasts,
fibroblasts, and hepatocytes
32. However, it has not been determined
whether Ago2 alterations can contribute to miRNA expression and
the RNAi response. In this study, we show that Ago2 up-regulation
by resveratrol leads to an increase in tumour-suppressive miRNAs
and the enhancement of RNAi activity.
Pterostilbene has anti-diabetic properties and has been shown to
be cytotoxic to a number of cancer cell lines in vitro
29,30. Although
pterostilbene and resveratrol have similar pharmacological prop-
erties, pterostilbene contains two methoxy groups and one hydroxyl
group, while resveratrol has three hydroxyl groups (Supplementary
Fig. 9). A recent study demonstrated that pterostilbene shows 95%
bioavailability when orally administered, while resveratrol only has
20% bioavailability
33. Furthermore, pterostilbene is a more powerful
chemopreventive agent than resveratrol in colon cancer
34, showing
that pterostilbene has several key advantages over resveratrol. In this
study,wedemonstratethatpterostilbeneismorereliablethanresver-
atrol in mediating the anti-cancer effect by inducing tumour-sup-
pressivemiRNAsandAgo2expression.Thereasonforthedifference
in the anti-cancer activity of pterostilbene and resveratrol in cancer
cells may be due to the expressed miRNAs.
It has been demonstrated that most tumours are characterised by
globally diminished miRNA expression
16,17,35. Thus, the delivery of
tumour suppressive miRNAs may allow for the therapeutic restitu-
tion of physiological regulation programs lost in cancer and other
disease states. However, miRNA therapy shares many of the disad-
vantages of other treatment approaches including delivery limita-
tions and instability. Therefore, novel methods are required to
resolve these issues. Based on this study, we hypothesise that the
down-regulation of miRNAs in cancer cells is compensated by
resveratrol, which induces the derepression of tumour suppressive
miRNAs.Down-regulationofoncogenicmiRNAsandup-regulation
of tumour-suppressive miRNAs by resveratrol in prostate cancer
cells has been reported
36; however, the connection between resvera-
trol and the miRNA biogenesis machinery has not been investigated
in detail. In this report, we demonstrated that resveratrol leads to a
reduction in malignancy by not only activating tumour-suppressive
miRNA transcription (Figs. 1d and 2b) but also enhancing the RNAi
activity mediated by Ago2 induction (Figs. 2d, e, f and g). Our
Table 1 | AlistofmiRNAswhichwereup-regulatedmorethan2.0-
fold by resveratrol in MDA-MB-231-luc-D3H2LN cells compared
with control
miRNA Fold change
Tumor-suppressive miRNA
hsa-miR-141 4.48
hsa-miR-26a 2.33
hsa-miR-195 3.38
hsa-miR-126 2.41
hsa-miR-185 2.75
hsa-miR-340 11.07
hsa-miR-128 2.13
hsa-miR-34a 2.65
hsa-miR-193b 2.58
hsa-miR-335 2.42
hsa-miR-200c 3.47
hsa-miR-196a 2.67
hsa-miR-497 4.60
hsa-miR-125a-3p 3.00
Onco- miRNA
hsa-miR-378* 4.81
hsa-miR-10b 5.11
hsa-miR-132 7.23
hsa-miR-222 2.40
www.nature.com/scientificreports
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multifocal carcinogenesis model in the absence of measurable tox-
icity provides proof of the principle that miRNA replacement by
resveratrolmaybeaclinicallyviableanti-cancertherapeuticstrategy.
In conclusion, this study shows that an orally available small
molecule can safely reduce many of the negative consequences at
doses acceptable in humans with an overall improvement in health
and survival. Our results raise the possibility that the regulation of
tumour-suppressive miRNAs by natural agents could be a novel
strategy in the design of combinational approaches using conven-
tional therapies for tumour recurrence prevention and in achieving
successful treatment outcomes in patients with cancer.
Methods
Reagents. Trans-resveratrol (98% purity) was purchased from Cayman Chemical,
pterostilbene (98% purity) from Tokyo Chemical Industry, cycloheximide solution
and 5, 6-dichlorobenzimidazole riboside from sigma, and docetaxel from Sanofi-
Aventis. The antibiotic solution (containing 10,000 U/mL penicillin and 10 mg/mL
streptomycin), the trypsin-EDTA mixture (containing 0.05% trypsin and EDTA),
and FBS (fetal bovine serum) were obtained from Invitrogen. The FITC-conjugated
anti-CD44 (clone L178) antibody was obtained from Becton Dickinson, and the
APC-conjugated anti-CD24 (clone ML5) antibody, from Biolegend. The duplexes of
each small interfering RNA (siRNA), targeting human Ago2 mRNA (siAgo2-1,
GCACGGAAGUCCAUCUGAAUU, UUCAGAUGGACUUCCGUGCUU; siAgo2-
2, GCAGGACAAAGAUGUAUUAUU, UAAUACAUCUUUGUCCUGCUU;
siAgo2-3, GGGUCUGUGGUGAUAAAUAUU, UAUUUAUCACCACAGACCC-
UU; siAgo2-4, GUAUGAGAACCCAAUGUCAUU, UGACAUUGGGUUCUCAU-
ACUU) and negative control 1 were purchased from Applied Biosystems
37.
Plasmids. The primary-miR-143 expression vector was purchased from TaKaRa
BIO. The full-length human Ago2 cDNA was cloned into pIRES2-EGFP vector
(Clontech). We amplified the upstream of human Ago2 gene (21,770/21 relative to
the TSS) by PCR using human genomic DNA as template, and we cloned it into the
pGL3-Basic vector. For the 39UTR reporter plasmids, the nucleotides 13,399 to
13,953 of human ZEB1 cDNA were amplified and cloned downstream of the
luciferase gene in the psiCHECK2 vector (Promega). For cloning the following
primers were used for PCR: Ago2 promoter: 59-ACGCGTATAGGGGATATGT-
GAAGGAGACA-39 (forward) and 59-CTCGAGATA CGCGCGCGCCACGGG-
CCCCG-39 (reverse); ZEB1 39UTR Fragment: 59-ATAATACGCGTTAAAGGA-
AGCTGATTAATTAGATATGC-39 (forward) and 59-ATAATAAGCTTTTTGTA-
GTGCAGAAGTTCTCACATTTT-39 (reverse)
22.
Cell culture. HEK293 cells (American Type Culture Collection) were cultured in
Dulbecco’s Modified Eagle’s Medium containing 10% heat-inactivated FBS and an
antibiotic-antimycotic (Invitrogen) at 37uCi n5 %C O 2. MDA-MB-231 cells
(American Type Culture Collection) and MDA-MB-231-luc-D3H2LN cells
(Xenogen) were cultured in RPMI containing 10% heat-inactivated FBS and
antibiotic-antimycotic at 37uCi n5 %C O 2. Human mammary carcinoma cell lines,
MCF7 cells and multidrug-resistant MCF7-ADR cells were provided by Shien-Lab,
Figure 3 | Multiple anti-cancer effects of tumour-suppressive miRNAs induced by resveratrol. (a) MDA-MB231-luc-D3H2LN cells were grown and
transiently transfected with anti-miR-141 or anti-miR-NC (control). After 4 hours, the cells were treated with resveratrol or DMSO (control) for 1 day
and subjected to an invasion assay. Representative photographs (upper panel) and quantification (lower panel) are shown. Scale bar: 100 mm. (b)MDA-
MB231-luc-D3H2LN cells were cultured and transiently transfected with anti-miR-143 or anti-miR-NC (control). After 4 hours, the cells were treated
with resveratrol or DMSO (control) for 72 hours, and the cell viability was measured by the MTS assay. (c) MDA-MB231 cells were treated with
resveratrol or DMSO (control). After 2 days of culture, the cell extract was subjected to real-time mRNA qRT-PCR. (d) MDA-MB231 cells were grown
andtransientlytransfectedwithaZEB-139UTRorpsiCheck2vector(control)underresveratroltreatment.After1dayofculture,thecellsweresubjected
to a luciferase reporter assay. The values on the y-axis are depicted relative to the luciferase activity of cells treated with DMSO, which is defined as 1 (all
data are shown as the mean 6 s.e.m., *P,0.05).
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maintained in RPMI supplemented with 10% heat-inactivated FBS and antibiotic-
antimycotic at 37uCi n5 %C O 2. MCF10A cells, which were a spontaneously
immortalized nontumorigenic epithelial cell line, (American Type Culture
Collection) were maintained in an MEBM medium with 1% GA-1000, 50 mg/ml
hydrocortisone,1mg/mlhEGF,500mg/mlinsulin,and4%BPE(Lonza)at37uCin5%
CO2.
Cellproliferation assay(MTS assay).Fivethousandcellsper wellwereseeded in 96-
well plates. The following day, the cells were treated with resveratrol. After 3 days of
culture, cell viability was measured using the Tetra Color One assay kit (Seikagaku
Kohgyo) according to the instructions of the manufacturer. The absorbance at
450 nm was measured using Envision (Wallac).
Transwell invasion assay. Breast cancer cell invasion was assayed in 24-well Biocoat
Matrigel invasion chambers (8 mm; Becton Dickinson) according to the
manufacturer’s protocol. Briefly, the cells were treated with resveratrol, and on the
following day, 20,000 cells were plated in the upper chamber. The upper chamber
contained resveratrol and the bottom chamber contained 10% FBS as a
chemoattractant.Twenty-twohourslater,thenon-invasivecellswereremovedwitha
cotton swab. The cells that migrated through the membrane and stuck to the lower
surface of the membrane were fixed with methanol and stained with Diff Quick
staining. For quantification, the cells were counted under a microscope in four
random fields. All assays were performed in triplicate. The data are expressed as the
invasionpercentagethroughtheMatrigelmatrixandmembranerelativetomigration
through the control membrane according to the manufacturer’s instructions.
Cell growth inhibitionby cytotoxic agentsandresveratrol. Breast cancer cells were
plated as described above and allowed to attach overnight. The cultures were
replenished with fresh medium containing 25 mM resveratrol for 24 hours and then
exposed to 2.5 nM of the chemotherapeutic agent docetaxel for an additional
48 hours. Thus, for a single-agent treatment, the cells were exposed to resveratrol or
docetaxel for 72 hours. The effect of resveratrol pretreatment on cell viability was
examined by the MTS assay method.
Figure 4 | Effects of pterostilbene on human breast cancer cells. (a) MDA-MB231-luc-D3H2LN cells were cultured in the presence or absence of
resveratrol or pterostilbene at the indicated concentrations for72 hours. Cellviability wasmeasured using the MTS assay. The control wells were treated
withDMSO.(b),(c)ExpressionlevelsofmiR-143,miR-200c(b),andAgo2(c)inMDA-MB231-luc-D3H2LNcells.Theexpressionlevelsoftheindicated
miRNAs were examined in MDA-MB231-luc-D3H2LN cells 48 hours after treatment with pterostilbene. (d) MDA-MB231-luc-D3H2LN cells were
treatedwithstilbenesfor72 hours,andAgo2expressionwasdetectedbyimmunoblotting.Actinwasusedasaloadingcontrol.(e)Modeloftheregulation
oftumour-suppressive miRNAs andAgo2expressioninthestilbenefamily (alldataareshownasthemean 6s.e.m.,*P,0.05,**P,0.01,***P,0.001).
www.nature.com/scientificreports
SCIENTIFIC REPORTS | 2 : 314 | DOI: 10.1038/srep00314 7Cell sorting and flow cytometric analysis. MDA-MB-231-luc-D3H2LN cells were
treated with resveratrol. After culturing for 3 days, MDA-MB-231-luc-D3H2LN cells
were suspended in their culture medium and subjected to a JSAN cell sorter (Bay
Bioscience). At least one million cells were pelleted by centrifugation at 180 x g for 5
minutes at 4uC, resuspended in a 5-mL mixture of a monoclonal mouse anti-human
CD44-FITC antibody (Becton Dickinson, clone L178) and a monoclonal mouse anti-
human CD24-APC antibody (Biolegend, clone ML5), and incubated for 30 minutes at
4uC. Three independent experiments were performed.
Mammosphere assay. The CD441/CD242 fraction from MDA-MB-231-luc-
D3H2LN cells were resuspended in 151 DMEM/F12 (Invitrogen) basal medium
freshly supplemented with 20 ng/mL human basic fibroblast growth factor
(Invitrogen), 20 ng/mL epidermal growth factor (Invitrogen), 10 mg/mL heparin
(Sigma-Aldrich), and 1550 B27 supplement without vitamin A (Sigma-Aldrich) and
seeded in 10-cm Ultra-Low Attachment Surface plates(Corning) at a density of 5000
cells. Ten days later, the plates were analysed for mammosphere formation.
Tumourigenicity assays in SCID hairless outbred mice. Six-week-old female SCID
hairless outbred (SHO) mice were subcutaneously injected with 200 MDA-MB231-luc-
D3H2LN cells in 25 mLo fP B Sa n d2 5mLo fm a t r i g e l( n55). The mice were then treated
with resveratrol (25 mg/kg/day) or ethanol (control) by intraperitoneal injection every
day for 8 days. The tumour growth was monitored by injecting luciferin in the mice
followed by measuring bioluminescence using an IVIS imaging system. The data were
analysed using the LIVINGIMAGE 2.50 software (Xenogen). Six-week-old female SCID
Hairless Outbred (SHO) mice were subcutaneously injected with 2000 MDA-MB231-
luc-D3H2LN cells in 25 mLo fP B Sa n d2 5mLo fM a t r i g e l( n5 5). The mice were then
treated with resveratrol (25 mg/kg) by intraperitoneal injection (IP) every day for 2 weeks
and then with docetaxel (20 mg/kg) by intraperitoneal injection (IP) once per week for 2
weeks. The normalised fold changes (day 22 or day 29/day 15) of bioluminescence
emitted from the whole body of the mice are shown.Allexperimental protocols involving
animals were approved by the the Institute for Laboratory Animal Research, National
Cancer Center Research Institute.
Isolation of microRNAs. Total RNAs were extracted from cultured cells using the
QIAzol and miRNeasy Mini Kit (Qiagen) according to the manufacturer’s protocol.
Quantitative Real-Time PCR (qRT-PCR). The qRT-PCR method has been
previously described
38. PCR was performed in 96-well plates using the 7300 Real-
Time PCR System (Applied Biosystems). All reactions were performed in triplicate.
All of the TaqMan microRNA assays were purchased from Applied Biosystems.
hRNU6 was used as an invariant control. SYBR Green I qRT-PCR was performed,
and the b-actin housekeeping gene was used to normalise the variation in the cDNA
levels. The following pairs of primers were used for gene amplification: for pri-miR-
16, 59-GCAATTACAGTATTTTAAGAGATGAT-39 (forward) and 59- CAT-
ACTCTACAGTTGTGTTTTAATGT-39 (reverse); for pri-miR-141-200c, 59-
TGAGCTTGGGACTGCAGAG-39 (forward) and 59-CTGAGCCACCTTCCCC-
TAC-39 (reverse); for pri-miR-143, 59-CAAGGTTTGGTCCTGGGTGCTCAAA-39
(forward)and59-TGGTGGCCTGTGGCGGGACTCCAA-39(reverse);forZEB1,59-
AAGAATTCACAGTGGAGAGAAGCCA-39 (forward) and 59-CGTTTCTTGC-
AGTTTGGGCATT-39 (reverse); for E-cadherin, 59-GTCCTGGGCAG-
ACTGAATTT-39(forward)and59-GACCAAGAAATGGATCTGTGG-39(reverse);
and for b-actin, 59-GGCACCACCATGTACCCTG-39 (forward) and 59-CACGG-
AGTACTTGCGCTCAG-39 (reverse)
39.
Quantification of the Ago2 mRNA half-life. MDA-MB231-luc-D3H2LN cells were
incubated with 5,6-dichlorobenzimidazole riboside (50 mM), which is an inhibitor of
mRNAsynthesis.Thecellswerethentreated with50mMresveratrolandharvestedat
the indicated time points. Total cellular RNA was isolated using the RNeasy Mini kit
(Qiagen). qRT-PCR analysis of Ago2 mRNA at each time point was performed as
described above. The fold-change in the Ago2 mRNA abundance at each time point
was determined by the following equation:
Fold change 5 2
2DCT, where DCT 5 (CT, Ago2) target - (CT, Ago2) 0 h.
Transient transfection assays. The plasmid transfections were performed using
Lipofectamine LTX (Invitrogen). The cell numbers and amount of plasmids for each
transfection were determined according to the manufacturer’s protocol. The
transfection of siRNA and miRNA inhibitors was accomplished using the
DharmaFECT transfection reagent (Thermo Scientific) according to the
manufacturer’s protocol.
Luciferasereporterassay.Cellswereseededin96-wellplatesat3000cellsperwellthe
day before transfection. A total of 500 ng of Ago2 vector, 10 nM siRNA against
luciferase and the AllStars negative control were added to each well. The cells were
collected1,3,or5daysaftertransfectionandanalysedusingtheBright-GloLuciferase
Reporter Assay System (Promega).
Immunoblot analysis. SDS-PAGE gels were calibrated using Precision Plus protein
standards (161-0375) (Bio-Rad), and anti-Ago2 (15200) and anti-actin (151,000)
were used as the primary antibodies. The dilution ratio of each antibody is indicated
in parentheses. A peroxidase-labelled anti-mouse secondary antibody was used at a
dilution of 1510,000. Bound antibodies were visualised by chemiluminescence using
the ECL Plus Western blotting detection system (RPN2132) (GE HealthCare), and
luminescentimageswereanalysedusingaLuminoImager(LAS-3000;FujiFilmInc.).
Quantification of Ago2 protein half-life. MDA-MB-231-luc-D3H2LN cells at 80%
confluency were treated with 30 mg/ml cycloheximide (Sigma-Aldrich). The cells
were then treated with 50 mM resveratrol and harvested at the indicated time points.
The effect of resveratrol on Ago2 stability was examined by immunoblotting as
reported above.
Statisticalanalysis.Thedatapresentedinbargraphsarethemeans6s.e.m.ofatleast
three independent experiments. Statistical analyses were performed using the
Student’s t-test.
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